KBroVet-CA1 500mg 60 Chewable

List Price: ~~$74.99~~
Sale Price: $67.70

Code: PRN0-0129

Enter pet & vet info at checkout

Let us contact your vet for you
Have your vet call or fax us
Mail us the original prescription

Product Info:

KBroVet-CA1 is an antiepileptic for use in dogs only. The chewable tablets are flavored and contain potassium bromide (KBr). KBr is thought to exert its antiepileptic activity by raising the seizure threshold, and stabilizing neurons against excitatory input from the area of the brain where the seizure originates. This drug should not be used in animals with a history of hypersensitivity to bromide. KBroVet-CA1 is conditionally approved by the FDA pending a full demonstration of effectiveness.

For:

Dogs

Benefits:

-Long-lasting Support for Seizure Control: Works by providing a consistent and reliable source of potassium bromide to help control seizures associated with idiopathic epilepsy in dogs, improving quality of life.
-Veterinarian-Recommended Solution: The first FDA conditionally approved drug demonstrated to be safe with a reasonable expectation of effectiveness.
-1x Per Day Chewable Tablets: Convenient daily dosing that helps ensure you don’t miss giving your dog a dose.
-Dog-Friendly Flavor: French vanilla-flavored tablets are formulated specifically for dogs, making medication time feel like a treat for your companion.
-Easy on dogs’ livers: An ideal choice for dogs with compromised liver function that cannot tolerate antiepileptics that are processed in the liver.

We directly source prescription medications from manufacturers and wholesale distributors registered with the FDA and licensed by applicable state boards. Guaranteed genuine, and where applicable, backed by the manufacturer.

Side Effects:

In a retrospective field study of 51 dogs diagnosed with idiopathic epilepsy and receiving only KBr to control seizures associated with idiopathic epilepsy, adverse reactions were documented for the initial 60 days of treatment. Increased appetite, weight gain, vomiting/regurgitation and sedation were the most common clinical abnormalities documented in the 60 day period after start of KBr therapy. Adverse reactions were also documented during the 30 days prior to KBr sample submission. Weight gain, weakness, ataxia, and increased appetite were the most common adverse reactions documented during this time period. Adverse events associated with concurrent use of KBr with other antiepileptic drugs such as phenobarbital have been reported. Neurologic signs were the most common adverse event and included sedation, irritability, restlessness, depression, behavioral changes, ataxia, hind limb paresis, mydriasis, stupor, and coma. The neurologic signs were reported to be reversible.